LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Allogene Therapeutics Inc

Fermé

SecteurSoins de santé

0.94 -16.07

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.84

Max

1.08

Chiffres clés

By Trading Economics

Revenu

6.4M

-60M

BPA

-0.28

Employés

226

EBITDA

6.8M

-56M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+626.5% upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-201M

256M

Ouverture précédente

17.01

Clôture précédente

0.94

Sentiment de l'Actualité

By Acuity

43%

57%

13 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 mai 2025, 23:40 UTC

Actions en Tendance

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 mai 2025, 23:33 UTC

Principaux Mouvements du Marché

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 mai 2025, 23:25 UTC

Principaux Mouvements du Marché

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 mai 2025, 23:25 UTC

Résultats

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mai 2025, 22:58 UTC

Résultats

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 mai 2025, 21:35 UTC

Résultats

Cisco Systems Names Patterson as CFO, Patel as President

14 mai 2025, 23:59 UTC

Market Talk

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 mai 2025, 23:49 UTC

Market Talk

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 mai 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2025, 23:48 UTC

Market Talk

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 mai 2025, 23:47 UTC

Market Talk

Gold Gains on Possible Technical Recovery -- Market Talk

14 mai 2025, 23:34 UTC

Acquisitions, Fusions, Rachats

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 mai 2025, 23:10 UTC

Résultats

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mai 2025, 23:07 UTC

Résultats

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 mai 2025, 23:00 UTC

Actualités

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 mai 2025, 22:43 UTC

Résultats

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 mai 2025, 22:34 UTC

Résultats

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 mai 2025, 22:33 UTC

Résultats

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero Did Not Declare a Dividend>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 mai 2025, 22:28 UTC

Résultats

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 mai 2025, 22:28 UTC

Résultats

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 mai 2025, 22:27 UTC

Résultats

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 mai 2025, 22:27 UTC

Résultats

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 mai 2025, 22:23 UTC

Actualités

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 mai 2025, 22:15 UTC

Résultats

Correction to Cisco Earnings Article -- WSJ

14 mai 2025, 21:48 UTC

Résultats

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 mai 2025, 21:37 UTC

Résultats

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

626.5% hausse

Prévisions sur 12 Mois

Moyen 8.5 USD  626.5%

Haut 14 USD

Bas 4 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

11

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

1.18 / 1.69Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

13 / 382Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.